$MED
MEDIFAST INC Stock $med

$med Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023004341 Filed on February 21, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$349.0M	$337.2M	$1.599B
YoY Change	-16.43%	-10.74%	4.75%
Cost Of Revenue	$102.6M	$103.6M	$458.2M
YoY Change	-11.03%	4.12%	14.97%
Gross Profit	$246.4M	$233.6M	$1.140B
YoY Change	-18.49%	-16.06%	1.14%
Gross Profit Margin	70.6%	69.27%	71.34%
Selling, General & Admin	$192.9M	$199.8M	$955.6M
YoY Change	-21.97%	-13.26%	4.86%
% of Gross Profit	78.28%	85.53%	83.79%
Research & Development	$1.000M	$1.200M	$4.500M
YoY Change	11.11%	9.09%	2.27%
% of Gross Profit	0.41%	0.51%	0.39%
Depreciation & Amortization	$2.974M	$2.954M	$10.98M
YoY Change	21.69%	-738.01%	61.19%
% of Gross Profit	1.21%	1.26%	0.96%
Operating Expenses	$192.9M	$201.0M	$960.1M
YoY Change	-21.97%	-13.16%	4.84%
Operating Profit	$53.51M	$32.60M	$184.8M
YoY Change	-2.86%	-30.4%	-14.54%
Interest Expense	-$181.0K	-$182.0K	-$701.0K
YoY Change	90.53%	95.7%	203.46%
% of Operating Profit	-0.34%	-0.56%	-0.38%
Other Income/Expense, Net	-$182.0K	-$9.000K	-$747.0K
YoY Change	63.96%	-228.57%	566.96%
Pretax Income	$53.33M	$32.41M	$184.1M
YoY Change	-3.0%	-30.68%	-14.84%
Income Tax	$13.36M	$5.890M	$40.49M
% Of Pretax Income	25.05%	18.17%	22.0%
Net Earnings	$39.97M	$26.52M	$143.6M
YoY Change	-4.34%	-22.06%	-12.48%
Net Earnings / Revenue	11.45%	7.86%	8.98%
Basic Earnings Per Share	$3.68		$12.82
Diluted Earnings Per Share	$3.67	$2.41	$12.73
COMMON SHARES
Basic Shares Outstanding	10.84M shares	10.93M shares	11.20M shares
Diluted Shares Outstanding	10.90M shares		11.28M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.7M	$87.69M	$87.69M
YoY Change	-48.45%	-58.97%	-19.95%
Cash & Equivalents	$123.7M	$87.69M	$87.69M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$9.674M	$16.24M	$16.24M
YoY Change	-26.86%	-0.59%	-0.59%
Inventory	$96.90M	$118.9M	$118.9M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$230.3M	$222.8M	$222.8M
YoY Change	-28.97%	-27.4%	-27.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$55.96M	$57.19M	$75.65M
YoY Change	-3.19%	1.88%	-6.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.71M	$12.46M	$17.78M
YoY Change	13.99%	92.58%	63.58%
Total Long-Term Assets	$91.29M	$93.43M	$93.43M
YoY Change	-6.06%	2.15%	2.15%
TOTAL ASSETS
Total Short-Term Assets	$230.3M	$222.8M	$222.8M
Total Long-Term Assets	$91.29M	$93.43M	$93.43M
Total Assets	$321.6M	$316.2M	$316.2M
YoY Change	-23.69%	-20.61%	-20.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$113.3M	$134.7M	$58.67M
YoY Change	-35.02%	-17.52%	-17.25%
Accrued Expenses	$5.411M	$5.776M	$54.80M
YoY Change	-18.79%	-11.45%	-25.65%
Deferred Revenue		$7.357M
YoY Change		-8.61%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$131.7M	$140.9M	$140.9M
YoY Change	-27.23%	-17.04%	-17.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$18.96M	$20.28M	$20.28M
YoY Change	-22.21%	-22.08%	-22.08%
Total Long-Term Liabilities	$18.96M	$20.28M	$20.28M
YoY Change	-22.21%	-22.08%	-22.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$131.7M	$140.9M	$140.9M
Total Long-Term Liabilities	$18.96M	$20.28M	$20.28M
Total Liabilities	$150.7M	$161.2M	$161.2M
YoY Change	-26.63%	-17.71%	-17.71%
SHAREHOLDERS EQUITY
Retained Earnings	$151.8M	$139.9M
YoY Change	-25.23%	-26.52%
Common Stock	$11.00K	$11.00K
YoY Change	-8.33%	-8.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$170.9M	$155.0M	$155.0M
YoY Change
Total Liabilities & Shareholders Equity	$321.6M	$316.2M	$316.2M
YoY Change	-23.69%	-20.61%	-20.61%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$39.97M	$26.52M	$143.6M
YoY Change	-4.34%	-22.06%	-12.48%
Depreciation, Depletion And Amortization	$2.974M	$2.954M	$10.98M
YoY Change	21.69%	-738.01%	61.19%
Cash From Operating Activities	$64.06M	$51.74M	$194.6M
YoY Change	46.68%	-793.65%	105.8%
INVESTING ACTIVITIES
Capital Expenditures	$2.115M	$9.064M	$16.68M
YoY Change	-29.71%	-177.98%	-51.24%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$5.267M
YoY Change	-100.0%		2.37%
Cash From Investing Activities	-$2.115M	-$9.064M	-$11.41M
YoY Change	19.9%	-22.02%	-60.73%
FINANCING ACTIVITIES
Cash Dividend Paid	$19.16M		$71.62M
YoY Change	15.02%		12.16%
Common Stock Issuance & Retirement, Net			$126.4M
YoY Change			125.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$25.90M	-24.33M	-$199.6M
YoY Change	-7.91%	-22.1%	59.5%
NET CHANGE
Cash From Operating Activities	$64.06M	51.74M	$194.6M
Cash From Investing Activities	-$2.115M	-9.064M	-$11.41M
Cash From Financing Activities	-$25.90M	-24.33M	-$199.6M
Net Change In Cash	$36.06M	18.34M	-$16.49M
YoY Change	160.9%	-136.46%	-72.3%
FREE CASH FLOW
Cash From Operating Activities	$64.06M	$51.74M	$194.6M
Capital Expenditures	$2.115M	$9.064M	$16.68M
Free Cash Flow	$61.94M	$42.68M	$177.9M
YoY Change	52.33%	924.61%	194.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000910329
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-31573
CY2022	dei	Entity Registrant Name EntityRegistrantName	Medifast, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3714405
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 International Drive
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21202
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Baltimore
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2022	dei	City Area Code CityAreaCode	410
CY2022	dei	Local Phone Number LocalPhoneNumber	581-8042
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	MED
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	2000000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10844844	shares
CY2022	dei	Auditor Firm AuditorFirmId	49
CY2022	dei	Auditor Name AuditorName	RSM US LLP
CY2022	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1598577000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1526087000	usd
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	934842000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	458163000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	398490000	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	237027000	usd
CY2022	us-gaap	Gross Profit GrossProfit	1140414000	usd
CY2021	us-gaap	Gross Profit GrossProfit	1127597000	usd
CY2020	us-gaap	Gross Profit GrossProfit	697815000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	955608000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	911356000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	563656000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	184806000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	216241000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	134159000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-701000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-231000	usd
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	246000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	119000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-140000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-747000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-112000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	106000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	184059000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	216129000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	134265000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40491000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52098000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31406000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	102859000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	12.82
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	8.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	12.73
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.89
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.68
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11195000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11705000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11771000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11276000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11813000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11850000	shares
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	6.56
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	5.68
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	4.52
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	102859000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-67000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	112000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-21000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-20000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-42000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	37000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-87000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	70000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	143481000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	164101000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	102875000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87691000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104183000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	118856000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	180043000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	5361000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	945000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16237000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16334000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	222784000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	306866000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57185000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56131000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18460000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24457000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12456000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6468000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	5328000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4404000	usd
CY2022Q4	us-gaap	Assets Assets	316213000	usd
CY2021Q4	us-gaap	Assets Assets	398326000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	134690000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	163309000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	428000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5776000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6523000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	140894000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	169832000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20275000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26020000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	161169000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	195852000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10928000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11594000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10873000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11593000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21555000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12018000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	111000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	139852000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	190333000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	54000	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	6398000	usd
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	155044000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202474000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	316213000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	398326000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	102859000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10980000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6812000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4316000	usd
CY2022	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	6098000	usd
CY2021	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	5069000	usd
CY2020	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	3189000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11053000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9903000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6796000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2130000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	usd
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-212000	usd
CY2022	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	14000	usd
CY2021	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	89000	usd
CY2020	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	320000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-924000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3715000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	601000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-61187000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	126651000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4621000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1373000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-945000	usd
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5169000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-97000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9887000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1086000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3412000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4543000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2741000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-37594000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	54380000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	28010000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	194570000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	94545000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	145196000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5267000	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5145000	usd
CY2020	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4605000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16681000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34209000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5887000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11414000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29064000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1282000	usd
CY2022	med	Proceeds From Stock Options Exercised Executives And Directors ProceedsFromStockOptionsExercisedExecutivesAndDirectors	0	usd
CY2021	med	Proceeds From Stock Options Exercised Executives And Directors ProceedsFromStockOptionsExercisedExecutivesAndDirectors	811000	usd
CY2020	med	Proceeds From Stock Options Exercised Executives And Directors ProceedsFromStockOptionsExercisedExecutivesAndDirectors	1597000	usd
CY2022	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	1516000	usd
CY2021	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	6089000	usd
CY2020	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	551000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	71620000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	63856000	usd
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	53190000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	126445000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55999000	usd
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-199581000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-125133000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-57144000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-67000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-21000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16492000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-59540000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	86749000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104183000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163723000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76974000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87691000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104183000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163723000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	37212000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	56758000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	24636000	usd
CY2022	us-gaap	Dividends Cash DividendsCash	19641000	usd
CY2021	us-gaap	Dividends Cash DividendsCash	17186000	usd
CY2020	us-gaap	Dividends Cash DividendsCash	13831000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	104832000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	102859000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	6796000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1597000	usd
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	551000	usd
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	5000000	usd
CY2020	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16000	usd
CY2020	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	53303000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	157246000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	9596000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	811000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6089000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	55999000	usd
CY2021	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	70000	usd
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	67192000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202474000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	11053000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1516000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	126445000	usd
CY2022	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	1000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-87000	usd
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	74002000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	155044000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span>
CY2022Q4	us-gaap	Due From Banks DueFromBanks	7400000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4500000	usd
CY2021Q4	us-gaap	Due From Banks DueFromBanks	12200000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our cash and cash equivalents and available-for-sale securities are maintained at several financial institutions and the balances with these financial institutions often exceed the amount of insurance provided on such accounts by the Federal Deposit Insurance Corporation. The cash and cash equivalents generally are maintained with financial institutions with reputable credit, and therefore bear minimal credit risk. Historically, we have not experienced any losses due to such concentration of credit risk.</span>
CY2022	us-gaap	Restructuring Costs RestructuringCosts	12200000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1700000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1600000	usd
CY2020	us-gaap	Advertising Expense AdvertisingExpense	4400000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4400000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2800000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12670000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	15196000	usd
CY2022Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	3611000	usd
CY2021Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	3641000	usd
CY2022Q4	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	8738000	usd
CY2021Q4	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	15991000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	97675000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	152687000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3838000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	7472000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	118856000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	180043000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	97126000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	88830000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39941000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32699000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57185000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56131000	usd
CY2022	us-gaap	Depreciation Depreciation	7900000	usd
CY2021	us-gaap	Depreciation Depreciation	5700000	usd
CY2020	us-gaap	Depreciation Depreciation	4100000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	58667000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	70894000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	23633000	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	28733000	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	19641000	usd
CY2021Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	17186000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13581000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	24940000	usd
CY2022Q4	med	Promotional Sales Incentive Accruals PromotionalSalesIncentiveAccruals	10240000	usd
CY2021Q4	med	Promotional Sales Incentive Accruals PromotionalSalesIncentiveAccruals	10935000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7357000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8050000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1571000	usd
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2571000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	134690000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	163309000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	102859000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11195000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11705000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11771000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	81000	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	108000	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	79000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11276000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11813000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11850000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	12.82
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	8.74
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	12.73
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.89
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.68
CY2022Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	21500000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10900000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	600000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1600000	shares
CY2019Q3	med	Stock Repurchase Program Additional Shares Authorized StockRepurchaseProgramAdditionalSharesAuthorized	2000000	shares
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	739000	shares
CY2021	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	238000	shares
CY2022Q4	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	1400000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	32000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	61000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	48.19
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	29000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	40.53
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	32000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	32000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	28000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	52.76
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	23000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	49.50
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	800000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1600000	usd
CY2022	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	9000	shares
CY2021	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	22000	shares
CY2020	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	6000	shares
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	184000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11053000	usd
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	116000	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9903000	usd
CY2020	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	156000	shares
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6796000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	24000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	90000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	21000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	111000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	87691000	usd
CY2022Q4	med	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	87691000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87691000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	109464000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	59000	usd
CY2021Q4	med	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	109544000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104183000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	5361000	usd
CY2021	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2020	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2022	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	35857000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	49433000	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	28520000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5558000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6380000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2285000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	41415000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	55813000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30805000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-738000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3424000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	477000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-186000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-291000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-77000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	201000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-924000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3715000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	601000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40491000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52098000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31406000	usd
CY2022	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	40500000	usd
CY2021	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	52200000	usd
CY2020	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	31400000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40491000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52098000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31406000	usd
CY2022	med	Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity	-27000	usd
CY2021	med	Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity	66000	usd
CY2020	med	Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity	14000	usd
CY2022	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	40464000	usd
CY2021	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	52164000	usd
CY2020	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	31420000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	38621000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	45405000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	28196000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	4635000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	4980000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1470000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.011
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-26000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1835000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.008
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-415000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.003
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	819000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.004
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	503000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.002
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	370000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.003
CY2022	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation	1470000	usd
CY2022	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent	0.008
CY2021	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation	2652000	usd
CY2021	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent	0.012
CY2020	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation	966000	usd
CY2020	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent	0.007
CY2022	med	Effective Income Tax Rate Reconciliation Charitable Donations EffectiveIncomeTaxRateReconciliationCharitableDonations	4316000	usd
CY2022	med	Effective Income Tax Rate Reconciliation Charitable Donations Percent EffectiveIncomeTaxRateReconciliationCharitableDonationsPercent	0.023
CY2021	med	Effective Income Tax Rate Reconciliation Charitable Donations EffectiveIncomeTaxRateReconciliationCharitableDonations	0	usd
CY2021	med	Effective Income Tax Rate Reconciliation Charitable Donations Percent EffectiveIncomeTaxRateReconciliationCharitableDonationsPercent	-0.000
CY2020	med	Effective Income Tax Rate Reconciliation Charitable Donations EffectiveIncomeTaxRateReconciliationCharitableDonations	0	usd
CY2020	med	Effective Income Tax Rate Reconciliation Charitable Donations Percent EffectiveIncomeTaxRateReconciliationCharitableDonationsPercent	-0.000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	396000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.002
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	468000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.002
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1342000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.010
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	427000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.002
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	808000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.004
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	16000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40491000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.220
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52098000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.241
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31406000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.234
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1069000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2022000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3713000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3052000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2374000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	420000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5153000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4240000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1781000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	3514000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	5773000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	7191000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2502000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1862000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	190000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2523000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1904000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21894000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18535000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4089000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5375000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	23000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	6000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1289000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1175000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	11165000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	7575000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P58M
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16566000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14131000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	5328000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	4404000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	31600000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	6700000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	5600000	usd
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	3600000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	7199000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	4504000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	101000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18872000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.021
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6243000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5693000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5825000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4160000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2553000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2858000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27332000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1281000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	26051000	usd

Files In Submission

Name	View Source	Status
med-20221231_lab.xml	Edgar Link	unprocessable
0001628280-23-004341-index-headers.html	Edgar Link	pending
0001628280-23-004341-index.html	Edgar Link	pending
0001628280-23-004341.txt	Edgar Link	pending
0001628280-23-004341-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
med-20221231.htm	Edgar Link	pending
med-20221231.xsd	Edgar Link	pending
med-20221231x10kxex211.htm	Edgar Link	pending
med-20221231x10kxex231.htm	Edgar Link	pending
med-20221231x10kxex311.htm	Edgar Link	pending
med-20221231x10kxex312.htm	Edgar Link	pending
med-20221231x10kxex32.htm	Edgar Link	pending
med-20221231_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
med-20221231_cal.xml	Edgar Link	unprocessable
med-20221231_def.xml	Edgar Link	unprocessable
med-20221231_pre.xml	Edgar Link	unprocessable
med-20221231_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MED
MEDIFAST INC Stock $med

2023 Q1 Form 10-K Financial Statement

#000162828023004341 Filed on February 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED MEDIFAST INC Stock $med

2023 Q1 Form 10-K Financial Statement

#000162828023004341 Filed on February 21, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED
MEDIFAST INC Stock $med